Takeda Pharmaceuticals USA and Cognition Kit have demonstrated the use of an Apple Watch wearable to monitor and evaluate cognition and mood in patients suffering from major depressive disorder (MDD).

Cognition Kit, a joint venture between Cambridge Cognition and Ctrl Group, designed the Apple Watch application (app) to facilitate patient assessment and monitoring outside of the lab.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The patients were found to be 95% compliant with mood evaluation and 96% for cognition monitoring on a daily basis with the wearable device.

The prospective observational study involved administration of brief cognitive and mood tests on an Apple Watch for 30 subjects aged 18-65 years and prescribed with antidepressant monotherapy.

Co-primary objectives of the study included feasibility and compliance of mood and cognitive measures on wearable technology, and comparison of the measures with standard neuropsychological tests and patient-reported outcomes on the symptoms of depression.

“The patients were found to be 95% compliant with mood evaluation and 96% for cognition monitoring on a daily basis with the wearable device.”

The abbreviated assessments through the wearable device were comparable with objective Cambridge Neuropsychological Test Automated Battery (CANTAB) cognitive tests and full-length PHQ-9 and PDQ-D patient-reported outcomes carried out in the first, third and sixth weeks.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, the results did not indicate any adverse events during the study period.

Takeda Pharmaceuticals USA external partnerships vice-president Nicole Mowad-Nassar said: “Technology may allow us to create real-time objective measurements for assessing effects in depression that could transform patient care by increasing our ability to estimate clinical conditions and support earlier engagement between the patient and clinician.

“We are encouraged by the study results and look forward to learning more about the intersection of technology and healthcare.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact